Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SFDA Bans Cash Transactions For Formulations Containing Controlled Substances

This article was originally published in PharmAsia News

Executive Summary

China's State FDA has issued a notice on tightening sales of formulations containing controlled substances to curb illicit extracts from formulated compounds which do not come under controlled drugs. Drug producers or distributors will be banned from cash transactions for some compound formulations, including those containing ephedrine, oral solutions containing codeine, diphenoxylate compound tablets and liquorice compound tablets. According to the notice, all companies with medicine trading licenses can operate the compound formulation business; however drug producers or distributors must file accounts information, and issue or ask for sales receipts when dealing with drugs. Wholesalers or firms that make the compound formulations directly for illegal drug producers will have their licenses revoked, and also face additional penalties. (Click here for more - Chinese Language)
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072579

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel